Savant Capital LLC Has $38.39 Million Position in Eli Lilly and Company (NYSE:LLY)

Savant Capital LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 49,730 shares of the company’s stock after selling 3,270 shares during the quarter. Savant Capital LLC’s holdings in Eli Lilly and Company were worth $38,391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. MFA Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 7.0% during the fourth quarter. MFA Wealth Advisors LLC now owns 366 shares of the company’s stock worth $283,000 after buying an additional 24 shares in the last quarter. Canvas Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 6.8% during the fourth quarter. Canvas Wealth Advisors LLC now owns 1,512 shares of the company’s stock valued at $1,167,000 after acquiring an additional 96 shares during the period. Liberty Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 4.7% during the fourth quarter. Liberty Capital Management Inc. now owns 2,250 shares of the company’s stock valued at $1,737,000 after acquiring an additional 100 shares during the period. LJI Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 1.8% during the fourth quarter. LJI Wealth Management LLC now owns 7,131 shares of the company’s stock valued at $5,505,000 after acquiring an additional 127 shares during the period. Finally, HTLF Bank lifted its holdings in shares of Eli Lilly and Company by 7.3% during the fourth quarter. HTLF Bank now owns 828 shares of the company’s stock valued at $639,000 after acquiring an additional 56 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective for the company. Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday. Finally, Bank of America reaffirmed a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $997.50.

Eli Lilly and Company Price Performance

Shares of LLY opened at $868.57 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a 50 day simple moving average of $789.87 and a 200 day simple moving average of $843.19. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The firm has a market capitalization of $824.55 billion, a PE ratio of 74.17, a P/E/G ratio of 1.87 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. Sell-side analysts predict that Eli Lilly and Company will post 23.33 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a $1.50 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s payout ratio is presently 44.41%.

Eli Lilly and Company announced that its board has approved a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.